

Câncer Renal

Bevacizumabe+ Interferon Alfa

Bevacizumabe: 10mg/kg	IV	D1, D14	
Interferon-alfa: 9 milhões UI	SC	3X/semana	
Por 1 ano			Ref. (1)

Interferon Alfa + Interleucina 2

Interferon alfa: 9 milhões U	SC	D1 a D4	
Interleucina 2: 12 milhões U	SC	D1 a D4 em 4 semanas	
a cada 6 semanas			Ref. (2)

Sunitinibe

Sunitinibe: 50mg	VO	D1 a D28	
a cada 6 semanas			Ref. (3)

Sorafenibe

Sorafenibe: 400mg	VO (2X/dia)	Contínuo	
sem interrupção			Ref. (4)

Tensirolimo

Tensirolimo: 25mg	IV	D1	Semanal
Ref. (5)			

Interferon Alfa

Interferon alfa: 5-15milhões/UI	SC	3-5X/semana	
Ref. (6)			

Interleucina 2

Interleucina 2: 720000UI/KG	IV	12/12H D1-5, 15-19	
8-12 semanas			Ref. (7)

Everolimo

Everolimo: 10mg VO dia Contínuo
Ref. (8)

Pazopanibe

Pazopanibe: 800mg VO dia Contínuo
Ref. (9)

1. Rini, B.I., Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 journal of clinical oncology, 2009. 27(18S): p. abstract 5020.
2. Atzpodien, J., *et al.* European studies of interleukin-2 in metastatic renal cell carcinoma. *Semin Oncol*, 1993. 20(6 Suppl 9): p. 22-6.
3. Motzer, R.J. and R.M. Bukowski, Targeted therapy for metastatic renal cell carcinoma. *J Clin Oncol*, 2006. 24(35): p. 5601-8.
4. Ratain, M.J., *et al.* Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2006. 24(16): p. 2505-12.
5. Hudes, G., *et al.* Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007. 356(22): p. 2271-81.
6. Minasian, L.M., *et al.* Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. *J Clin Oncol*, 1993. 11(7): p. 1368-75.
7. Acquavella, N., *et al.* Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. *J Immunother*, 2008. 31(6): p. 569-76.

8. Motzer, R.J., *et al.* Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008. 372(9637): p. 449-56.
9. Sternberg CN, *et al.* Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. *J Clin Oncol* 2010;28(6):1061-1068.